08:55:59 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-08 Kvartalsrapport 2024-Q1
2024-05-02 Ordinarie utdelning LIFE 0.00 NOK
2024-04-30 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-08 Ordinarie utdelning LIFE 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning LIFE 0.00 NOK
2022-05-06 Årsstämma 2022
2022-04-21 Bokslutskommuniké 2021
2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma 2021
2021-04-20 Bokslutskommuniké 2020
2020-06-26 Årsstämma 2020
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2023-11-28 08:00:00

Bergen, Norway, November 28th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare has placed the purchase order for a SEM (abbreviation for Scanning Electron Microscope) from the German supplier Carl Zeiss AG.

Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of August 20th, 2023, and later investor communication. The launch of an automated production line at Lifecare Laboratory by end of Q2 2024 is set as a major milestone.

In order to achieve this, the company now has placed the purchase order for the highly advanced and precise Zeiss XB350 electron microscope. The microscope is especially suitable for the purpose of Lifecare and the setup of the automated production line next year.

- This decision on the Zeiss XB350 is based on a comparison of diverse SEM suppliers. Based on pre-work that has been performed recently Lifecare is convinced that Zeiss offers the best SEM system solution in terms of reliable high-tech machinery, good support service, and availability of dedicated hardware and software solutions to enable Lifecare the automated batchwise production of Sencell sensors, says CSO Prof. Andreas Pfützner at Lifecare.

The purchase of the Zeiss microscope also coincides with communication from Lifecare on October 2nd when the company announced the purchase of software for automated production from Carl Zeiss IQS Deutschland GmbH.

The SEM is considered a key component to manufacture Lifecare’s unique sensor for Continuous Glucose Monitoring applying osmotic pressure as the sensing principle. . Sophisticated 3D-printing processes carried out in a SEM enables Lifecare to obtain the precision necessary to apply pressure sensing elements of a size as small as 40 nanometers (one nanometer corresponding to a millionth of a millimeter).

- The Scanning Electron Microscope with customized software is essential for our transition towards the industrial phase. Next year, the microscope will be used to reach our goals of pilot production in Q1 and automated production in Q2. The next step in our preparations will be to order nanofluidic dispensing machines to fill our reactive chemistry composition - developed at our entity Lifecare Chemistry Ltd in Bristol (UK) - to the sensors, says CEO Joacim Holter at Lifecare.